VolitionRx Limited Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
VolitionRx Limited (VNRX) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $180.47 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-15.
Discontinued › Notes › Stockholders' Equity Note
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2023-03-15
- VolitionRx Limited share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2022-12-31 was $30.20K.
- VolitionRx Limited share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2022-09-30 was $82.29K.
- VolitionRx Limited share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2021-12-31 was $0.00.
- VolitionRx Limited share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2021-09-30 was $0.00.
- VolitionRx Limited share-based payment arrangement, decrease for tax withholding obligation for fiscal 2022 was $180.47K, a 38.37% increase from fiscal 2021.
- VolitionRx Limited share-based payment arrangement, decrease for tax withholding obligation for fiscal 2021 was $130.43K.
- VolitionRx Limited share-based payment arrangement, decrease for tax withholding obligation for fiscal 2020 was -$187.47K.
- VolitionRx Limited share-based payment arrangement, decrease for tax withholding obligation for fiscal 2019 was $0.00.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 6 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 9 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month |
|---|---|---|---|---|
| 2022-12-31 | $30.20K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $112.48K derived: sum of 2 quarters · filed 2023-03-15 | $180.47K 10-K · filed 2023-03-15 | |
| 2022-09-30 | $82.29K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $150.28K 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | $67.99K 10-Q · filed 2022-08-10 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $0.00 derived: sum of 2 quarters · filed 2023-03-15 | $154.18K derived: sum of 3 quarters · filed 2023-03-15 | $130.43K 10-K · filed 2023-03-15 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $154.18K derived: sum of 2 quarters · filed 2022-11-14 | $130.43K 10-Q · filed 2022-11-14 | $130.43K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $154.18K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $130.43K 10-Q · filed 2022-08-10 | $130.43K derived: sum of 3 quarters · filed 2022-08-10 | |
| 2021-03-31 | -$23.76K 10-Q · filed 2021-05-11 | -$23.76K derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | -$187.47K 10-K · filed 2021-03-22 | ||
| 2020-09-30 | -$187.47K 10-Q · filed 2020-11-12 | |||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-11 | $0.00 derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | $0.00 10-K · filed 2021-03-22 | ||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |